Quantiphi, an AI-first digital engineering company today announced it has acquired a strategic minority interest in Transcell Biologics, a stem cell-based biotech innovator, marking a milestone in AI-supported drug discovery in the life sciences industry.
Quantiphi Global Head of Healthcare and Life Sciences Barinder Marhok said, “The strategic investment aligns with Quantiphi’s decade-plus commitment to solve what matters for enterprises. This partnership will help pharma ascertain the safety profile of their novel molecules on human stem cell composed micro physiologies, reduce the need for animal testing and accelerate preclinical decisions and batch release processes for biotherapeutics and vaccines.”
“Use of ethical and responsible AI will help with automated bioassay implementation and support scientists in accelerated decision-making processes,” he added.
Transcell Biologics Founder and CEO Subhadra Dravida said, “Quantiphi’s investment and involvement are crucial for advancing Transcell’s mission to support animal-free testing strategies as enterprise solutions. This collaboration aims to bring adult stem cell technology into practical applications and ultimately improve treatment outcomes. Through these synergistic efforts, we are propelling innovation and elevating industry standards for efficient cost and time management.”
Quantiphi Corporate Development Head Dipen Shah said, “Quantiphi and Transcell are seamlessly integrating AI and biotech to drive advancements in drug discovery and development processes. Quantiphi will continue to consider other strategic partnerships and investments across the value chain – from early-stage research to clinical trials – as aligned with our growth and innovation strategy to enhance customer value.”
Headquartered in Hyderabad, India, Transcell Biologics is a innovation-driven biotech entity developing a portfolio of best and first-in-class productized offerings by applying their in-house hypothesis: biobox platform technology.
